Micralyne launch MicraFluidics technology
Micralyne, manufacturer of biomedical MicroElectroMechanical Systems (MEMS) and sensors has announced the launch of the MicraFluidics technology "“ a line of standardized microfluidic process technologies to support high demand from the biomedical and life-sciences industry for rapid design and deployment of integrated microfluidic-based products.
The MicraFluidics technology is a highly functional and versatile set of standardized microfluidic processes featuring a variety of substrate options for biomedical customers such as silicon, glass and silicon-on-insulator (SOI) with design flexibility for multi-level channels, electrode patterning for dielectrophoresis and embedded sensors, and choices of glass or silicon as input and output ports. This technology has been validated in a wide range of devices such as: flow cells, biochips, lab-on-a-chip, cell sorters, separation and analysis devices, and high-pressure analytical chips.
"Micralyne has been on the forefront of microfluidic development, having first developed glass micromachining technology in the 1990's. Early devices were cavities in glass for cell manipulation, and quickly evolved to bonded channel devices. We have advanced the technology considerably over the last three decades, and are excited to offer these innovations as standard microfluidic processes", said Mr. Glen A. Fitzpatrick, Chief Scientific Officer, Micralyne. "It can be challenging to find foundries that manufacture microfluidic devices and meet the stringent quality compliance requirements of the biomedical industry. Micralyne is one of a handful of MEMS foundries with ISO 13485 certification", Mr. Fitzpatrick added.
Micralyne's MEMS Technology Platforms provide a modular approach to MEMS design and enable fast prototyping with semi-custom device implementations, and rapid manufacturing ramp-up without sacrificing product quality and consistency. Micralyne started providing standard processes and MEMS building blocks in 2006 with an effort to lower MEMS development costs and accelerate MEMS time-to-market for customers.
"Over the last two years we have seen a dramatic increase in demand from our customers for robust, miniaturized microfluidic biochips for a wide range of end applications, such as point-of-care diagnostics, treatment planning, drug delivery, and oncology research", said Paul Pickering, Chief Revenue officer, Micralyne Inc. "We understand that time-to-market is critical for our biomedical customers, and therefore have developed the MicraFluidics technology to enable our customers to rapidly convert their ideas to manufacturable products", Mr. Pickering added.
